New hope for tough liver cancers: triple therapy targets gene mutation
NCT ID NCT07535840
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in 25 adults with advanced liver cancer that has a TP53 gene mutation and has not responded to previous immunotherapy. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs intravenously and orally, and will be monitored for side effects and tumor response every 6 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESISTANT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.